Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 13/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807931 | 0.83 | F10 (0.49) | HAVCR2NPC1SMN1; SMN2MAPTRAB9A | |
| SCHEMBL6804794 | 0.80 | F10 (0.59) | NPC1SMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL6809084 | 0.79 | SMN1; SMN2 (0.66) | HAVCR2NPC1SMN1; SMN2MAPTRAB9A | |
| SCHEMBL6808403 | 0.79 | TP53 (0.45) | HAVCR2NPC1SMN1; SMN2MAPTRAB9A | |
| SCHEMBL6805032 | 0.78 | F10 (0.70) | MAPT | |
| SCHEMBL6808035 | 0.78 | GAA (0.56) | NPC1SMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL6804740 | 0.78 | HAVCR2 (0.64) | HAVCR2NPC1SMN1; SMN2MAPTRAB9A | |
| SCHEMBL6801213 | 0.78 | SMN1; SMN2 (0.54) | NPC1SMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL6298117 | 0.77 | F10 (0.56) | NPC1SMN1; SMN2MAPTRAB9AMEN1 | |
| SCHEMBL7098774 | 0.74 | PDE4A (0.46) | NPC1SMN1; SMN2MAPTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | claimed |
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | RCOR3, F2, NCOR2 | HAVCR2 226/4885NPC1 2490/4885SMN1; SMN2 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.